Results 71 to 80 of about 6,976 (185)

Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapy.

PLoS ONE
BackgroundCurrent evidence on circulating tumor DNA (ctDNA) in the adjuvant setting of early breast cancer (eBC) confirms its high prognostic value.
Kerstin Pfister, Thomas W P Friedl, Andreas Hartkopf, Franziska Mergel, Sophia Huesmann, Forca Mehmeti, Henning Schäffler, Angelina Fink, Tatjana Braun, Sabine Heublein, Lisa Wiesmüller, Klaus Pantel, Brigitte Rack, Peter A Fasching, Wolfgang Janni   +14 more
doaj   +1 more source

Efficacy and safety of trastuzumab deruxtecan therapy

Onkologija
Antibody-drug conjugates (ADCs) are a new generation of drugs that currently represent one of the most effective treatment options for cancer. ADCs target a specific target (antigen) that is selectively expressed on a tumour cell.
Nina Privšek, Simona Borštnar, Cvetka Grašič Kuhar   +2 more
doaj   +1 more source

Antibody-drug conjugates in breast cancer: current evidence and future directions

Experimental Hematology & Oncology
Antibody-drug conjugates (ADCs) are a rapidly evolving class of antitumor drugs and have already revolutionized the treatment strategy of many hematologic and solid cancers.
Ning Li, Lu Yang, Zixuan Zhao, Tian Du, Gehao Liang, Na Li, Jun Tang   +6 more
doaj   +1 more source

Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options

Cancer Management and Research, 2020
Simon Peter Gampenrieder,1,2 Vanessa Castagnaviz,1 Gabriel Rinnerthaler,1,2 Richard Greil1,2 1Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer ...
Gampenrieder SP, Castagnaviz V, Rinnerthaler G, Greil R   +3 more
doaj  

A Case of HER2 Mutated Colorectal Cancer Treated Successfully With Fam-Trastuzumab Deruxtecan [PDF]

, 2023
Aswanth Reddy, Nkolika Nwankwo, Arjun Sekar, Aswini Kumar   +3 more
openalex   +1 more source

The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate–resistant HER2-overexpressing breast cancer [PDF]

, 2023
Jangsoon Lee, Kumiko Kida, Huey Liu, Ganiraju C. Manyam, Young Jin Gi, Asha S. Multani, Jing Wang, Gitanjali Jayachandran, James M. Reuben, Lei Huo, Debu Tripathy, Naoto T. Ueno   +11 more
openalex   +1 more source

Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer

Nature Communications
HER2, encoded by the ERBB2 gene, is a receptor tyrosine kinase frequently activated in human cancers via gene amplification, mutation, and/or protein overexpression.
Ziyu Chen, Xinran Tang, Jordan E. Eichholz, Andrew Mcpherson, Jasmine Thomas, Karan Nagar, Naryan Rustgi, John R. Christin, Fengshen Kuo, Sizhi Gao, Hui Jiang, Jiaqian Luo, Irina Ostrovnaya, Merve Basar, Eugene Pietzak, Jonathan A. Coleman, Michael F. Berger, Elisa de Stanchina, Sohrab P. Shah, Neeman Mohibullah, David H. Aggen, Jonathan E. Rosenberg, Sarat Chandarlapaty, Michael M. Shen, Hikmat Al-Ahmadie, Gopa Iyer, Kwanghee Kim, David B. Solit   +27 more
doaj   +1 more source

Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer

, 2022
Tasmiyah Siddiqui, Payal Rani, Tayyaba Ashraf, Aayat Ellahi   +3 more
openalex   +1 more source

Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer

Nature Communications
Targeting the mitogen-activated protein kinase (MAPK) cascade in pancreatic ductal adenocarcinoma (PDAC) remains clinically unsuccessful. We aim to develop a MAPK inhibitor-based therapeutic combination with strong preclinical efficacy.
Ashenafi Bulle, Peng Liu, Kuljeet Seehra, Sapana Bansod, Yali Chen, Kiran Zahra, Vikas Somani, Iftikhar Ali Khawar, Hung-Po Chen, Paarth B. Dodhiawala, Lin Li, Yutong Geng, Chia-Kuei Mo, Jay Mahsl, Li Ding, Ramaswamy Govindan, Sherri Davies, Jacqueline Mudd, William G. Hawkins, Ryan C. Fields, David G. DeNardo, Deborah Knoerzer, Jason M. Held, Patrick M. Grierson, Andrea Wang-Gillam, Marianna B. Ruzinova, Kian-Huat Lim   +26 more
doaj   +1 more source

Antibody-drug conjugates in elderly patients with breast cancer

Breast
Breast cancer remains a leading cause of cancer-related mortality worldwide, with elderly patients (aged >65 years) comprising a substantial portion of those affected.
Marta Bonotto, Giulia De Pieri, Rocco Esposto, Ludovica Lay, Giuseppe Aprile, Fabio Puglisi, Alessandro Marco Minisini   +6 more
doaj   +1 more source